Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL496750 | 0.85 | NR5A2 (0.32) | — | |
| SCHEMBL2319289 | 0.83 | — | — | |
| SCHEMBL8066956 | 0.81 | — | — | |
| SCHEMBL6227757 | 0.80 | CYP2C19 (0.33) | CYP1A2CYP3A4CYP2C9TSHRCYP2C19 | |
| SCHEMBL1032613 | 0.78 | ALDH1A1 (0.30) | — | |
| SCHEMBL6687742 | 0.78 | NR5A2 (0.31) | CYP1A2CYP3A4CYP2C9TSHRCYP2C19 | |
| SCHEMBL7157828 | 0.75 | HDAC3 (0.33) | CYP1A2CYP3A4CYP2C9TSHRCYP2C19 | |
| SCHEMBL2895920 | 0.75 | HDAC3 (0.33) | CYP1A2CYP3A4CYP2C9TSHRCYP2C19 | |
| SCHEMBL20604058 | 0.75 | HDAC3 (0.33) | CYP1A2CYP3A4CYP2C9TSHRCYP2C19 | |
| SCHEMBL7159714 | 0.75 | HDAC3 (0.33) | CYP1A2CYP3A4CYP2C9TSHRCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050009967-A1 | Phosphite stabilizers and methods to preparation and polymer composition thereof | CROMPTON CORPORATION | 2005-01-13 | — | — | US | claimed |
| EP-1603874-A2 | G-LACTAM DERIVATIVES AS PROSTAGLANDIN AGONISTS | Applied Research Systems ARS Holding N.V. (AN) | 2005-12-14 | — | — | EP | disclosed |
| US-6911253-B2 | Porous resin film | YUPO CORPORATION (JP) | 2005-06-28 | — | — | US | disclosed |
| US-20050009967-A1 | Phosphite stabilizers and methods to preparation and polymer composition thereof | CROMPTON CORPORATION | 2005-01-13 | — | — | US | disclosed |
| WO-2004111158-A1 | PHOSPHITE STABILIZERS AND METHODS TO PREPARATION AND POLYMER COMPOSITION THEREOF | CHEMTURA CORPORATION (US) | 2004-12-23 | — | — | WO | disclosed |
| WO-2004078103-A2 | G-LACTAM DERIVATIVES AS PROSTAGLANDIN AGONISTS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2004-09-16 | — | — | WO | disclosed |
| US-20020012786-A1 | Blend of thermoplastic resin and fine powder; ink jet recording | YUPO CORPORATION (JP) | 2002-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009967-A1 | Phosphite stabilizers and methods to preparation and polymer composition thereof | PHOSPHO1, OR51E2, CDIPT | CYP1A2 4776/4885CYP3A4 3653/4885CYP2C9 3736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.